Drug survival rates in patients with psoriasis after treatment with biologics

Clinically, patients' adherence to biologic treatment is not only related to efficacy but also to adverse events, cost and other factors. To evaluate long‐term viability of biologic treatment, both the percentage of and reasons for discontinuation of treatment were investigated. In this study,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2013-12, Vol.40 (12), p.1008-1013
Main Authors: Umezawa, Yoshinori, Nobeyama, Yoshimasa, Hayashi, Mitsuha, Fukuchi, Osamu, Ito, Toshihiro, Saeki, Hidehisa, Nakagawa, Hidemi
Format: Article
Language:English
Subjects:
adalimumab
Adult
Aged
Antibodies, Monoclonal - therapeutic use
drug survival rate
Female
Follow-Up Studies
Humans
infliximab
Male
Medication Adherence - statistics & numerical data
Middle Aged
psoriasis
Psoriasis - drug therapy
Treatment Outcome
ustekinumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinically, patients' adherence to biologic treatment is not only related to efficacy but also to adverse events, cost and other factors. To evaluate long‐term viability of biologic treatment, both the percentage of and reasons for discontinuation of treatment were investigated. In this study, patients treated with infliximab (n = 38), adalimumab (n = 59) and ustekinumab (n = 30) were included and observed for 12 months. Clinical efficacy was evaluated using a 75% reduction of Psoriasis Area and Severity Index score (PASI‐75), and patients who discontinued treatment were considered as not having achieved PASI‐75. In addition, drug survival rate (DSR) was investigated. In patients treated with infliximab, PASI‐75 was 68.4% and DSR was 73.3% by the end of treatment. In patients treated with adalimumab, PASI‐75 was 50.8% and DSR was 79.7%. In patients treated with ustekinumab, PASI‐75 was 63.3% and DSR was 96.7%. Several patients discontinued treatment because of insufficient efficacy due to secondary failure in infliximab or primary failure in adalimumab. To increase treatment efficacy, it will be necessary for these patients to use an additional concomitant treatment. Higher efficacy is expected with biologics than with conventional treatments; however, the actual clinical efficacy over a long period of time may be insufficient if they are used without any concomitant treatments.
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.12353